Calendario›MBRX›WP1122

WP1122

Study to Assess the Safety and Pharmacokinetics of WP1122 in Healthy Volunteers

Ensayo de Moleculin Biotech, Inc. en Voluntarios sanos.

Fase

Fase 1

Estado

Completado

Participantes

48

previstos

Centros

1

Fin del objetivo primario

oct 2022

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, triple ciego. Comenzó en may 2022.

Qué mide

Safety in Single Ascending Dose (SAD) (del registro, en inglés) (5 semanas)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study in healthy human volunteers will investigate the effects of a single dose (SAD) and multiple days of dosing (MAD) of WP1122 administered as an oral (PO) solution. Dose escalation will take place in sequential SAD cohorts, and MAD will start as soon as SAD has completed at least 3 dosing cohorts in which WP1122 is found to be safe and well-tolerated. This study in healthy volunteers will explore safety and PK, and subsequent clinical development will be in patients infected with SARS CoV-2 in the setting of continued safety and favorable risk/benefit.

Más ensayos de MBRX

Todos los de MBRX, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT05195723), actualizada en feb 2023.